@article{ec2ca972ba3e4d5a985b9a3e5db3f7ae,
title = "Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials",
keywords = "Cardiovascular outcomes trial, Glucagon-like peptide-1 receptor agonist, HbA, Major adverse cardiovascular events, PIONEER 6, Post hoc analysis, Semaglutide, SUSTAIN 6, Type 2 diabetes",
author = "Mellbin, {Linda G.} and Bhatt, {Deepak L.} and David, {Jens Peter} and Kathrine Ekstr{\"o}m and Petrie, {Mark C.} and S{\o}ren Rasmussen and Tina Vilsb{\o}ll",
note = "Funding Information: This study was funded by Novo Nordisk. ",
year = "2024",
doi = "10.1093/eurheartj/ehae028",
language = "English",
volume = "45",
pages = "1371--1374",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",
}